Gennex Laboratories Ltd
BSE:531739
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gennex Laboratories Ltd
Cash from Investing Activities
Gennex Laboratories Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gennex Laboratories Ltd
BSE:531739
|
Cash from Investing Activities
₹74.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Investing Activities
-₹47.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Investing Activities
-₹28.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Investing Activities
-₹94.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Investing Activities
-₹59.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Investing Activities
-₹6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Gennex Laboratories Ltd
Glance View
Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing of bulk drugs, intermediaries and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which caters to both domestic and international markets.
See Also
What is Gennex Laboratories Ltd's Cash from Investing Activities?
Cash from Investing Activities
74.3m
INR
Based on the financial report for Dec 31, 2025, Gennex Laboratories Ltd's Cash from Investing Activities amounts to 74.3m INR.
